Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Blank, M.
Right arrow Articles by Eldor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blank, M.
Right arrow Articles by Eldor, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 14, No. 2, 121-129, February 2002
© 2002 Japanese Society for Immunology

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

Miri Blank, Yehuda Shoenfeld, Sigal Tavor1, Sonja Praprotnik2, Marie Claire Boffa3, Babette Weksler4, M. Jeanine Walenga5, Jean Amiral6 and Amiram Eldor,{dagger}

Research Unit of Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel
1 Institute of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
2 Department of Rheumatology, University Medical Centre, Vadnikova 62 1000, Ljubljana, Slovenia
3 INSERM U353, Hopital Saint-Louis, 13-75651 Paris, France
4 Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
5 Cardiovascular Institute, Loyola University Medical Center, Maywood, IL 60153, USA
6 Hyphen Biomed, Conflans St Honorine, France

Correspondence to: Y.Shoenfeld; E-mail: shoenfel{at}post.tau.ac.il

Heparin-induced thrombocytopenia (HIT) is a serious complication that occurs in ~1–5% of patients treated with heparin and may be associated with severe thrombotic events. HIT is mediated by antibodies directed mostly to epitope(s) formed by complexes between heparin or other anionic mucopolysaccharides and platelet factor 4 (PF4). Anti-PF4/heparin IgG antibodies from six patients with HIT were affinity purified and assessed for interaction with human microvascular and macrovascular endothelial cells (EC). The antibodies directly activated primary cultures of human bone marrow microvascular EC (HBMEC) and SV40 immortalized HBMEC (TrHBMEC) only in the presence of PF4, but did not activate macrovascular human umbilical vein EC (HUVEC) under the same conditions. These antibodies were found to bind to TrHBMEC through the F(ab)2 portion of the anti-PF4/heparin IgG. TrHBMEC activation was characterized by an augmented release of IL-6, von Willebrand factor, soluble thrombomodulin, and by an elevated expression of the adhesion molecules P-selectin, E-selectin and vascular cellular endothelial molecule-I to different degrees. Enhanced monocyte adhesion to PF4/heparin antibody-treated TrHBMEC (33–72% adhesion) was also observed. None of these effects occurred with unstimulated HUVEC. However, pre-treatment of HUVEC with tumor necrosis factor-{alpha} resulted in the same changes observed with microvascular EC exposed to the HIT antibodies. Our findings indicate that anti-PF4/heparin antibodies directly activate microvascular EC while interaction with macrovascular EC requires pre-activation. These results may explain some of the specific clinical manifestations in HIT.

Keywords: anti-platelet factor 4, heparin, microvascular endothelial cells, thrombocytopenia

{dagger} Deceased


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ChestHome page
E. Shantsila, G. Y. H. Lip, and B. H. Chong
Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management
Chest, June 1, 2009; 135(6): 1651 - 1664.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Z. Xiao, G. P. Visentin, K. M. Dayananda, and S. Neelamegham
Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion
Blood, August 15, 2008; 112(4): 1091 - 1100.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
D Alpert, L A Mandl, D Erkan, W Yin, E I Peerschke, and J E Salmon
Anti-heparin platelet factor 4 antibodies in systemic lupus erythaematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome
Ann Rheum Dis, March 1, 2008; 67(3): 395 - 401.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Y. Ramot and A. Nyska
Drug-Induced Thrombosis--Experimental, Clinical, and Mechanistic Considerations
Toxicol Pathol, February 1, 2007; 35(2): 208 - 225.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Davenport
Sudden collapse during haemodialysis due to immune-mediated heparin-induced thrombocytopaenia
Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1721 - 1724.
[Full Text] [PDF]


Home page
BloodHome page
L. Rauova, L. Zhai, M. A. Kowalska, G. M. Arepally, D. B. Cines, and M. Poncz
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
Blood, March 15, 2006; 107(6): 2346 - 2353.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. B. Beleslin-Cokic, V. P. Cokic, X. Yu, B. B. Weksler, A. N. Schechter, and C. T. Noguchi
Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells
Blood, October 1, 2004; 104(7): 2073 - 2080.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
T. E. Warkentin, W. C. Aird, and J. H. Rand
Platelet-Endothelial Interactions: Sepsis, HIT, and Antiphospholipid Syndrome
Hematology, January 1, 2003; 2003(1): 497 - 519.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.